Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-04 · accession 0001209191-22-016930 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-08 | 2022-03-04 | RARE | Fust Matthew K | Dir | M - OptEx | $40.37 | +7,500 | 23.2K | +48% | +$302.8K |
| D | 2022-03-08 | 2022-03-04 | RARE | Fust Matthew K | Dir | M - OptEx | $0.00 | -7,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-04 | M | A | 7,500 | $40.37 | 23,195 | D | — | — | (F1) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-04 | M | D | 7,500 | $0.00 | 0 | D | $40.37 · — to 2024-07-10 | 7,500 Common Stock | (F2) The option vested in full on on June 18, 2015. |